The effect of lasofoxifene on local mediators of bone resorption in the prevention of postmenopausal osteoporosis.

Trial Profile

The effect of lasofoxifene on local mediators of bone resorption in the prevention of postmenopausal osteoporosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2011

At a glance

  • Drugs Lasofoxifene (Primary)
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms LACE
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Jul 2011 Additional drug company added in associations field as reported by ClinicalTrials.gov record.
    • 01 Dec 2009 Results reported in Bone.
    • 12 Sep 2008 Results reported at ASBMS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top